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A  sandwich-type ELISA has been developed fo r the assess­
m ent o f complexes between urokinase-type plasminogen 
activator (uPA) and its receptor (uPAR) in extracts o f squa­
mous cell lung carcinomas. The assay is based on a combina­
tion of rabbit polyclonal anti-uPA antibodies and a biotinyl- 
ated mouse anti-uPAR monoclonal antibody (MAb). The 
detection lim it o f the assay is approxim ately 0.5 fm ol/m l. A  
linear dose-response is obtained w ith  up to  40 fm ol/m l of 
uPA:uPAR complexes, while uPA and uPAR separately do 
not cause any response in the ELISA. A  buffer which has been 
used previously fo r optim al extraction o f uPAR yields the  
highest amounts o f uPAiuPAR complexes. Absorption o f 
tu m o r extracts w ith anti-uPA o r anti-uPAR MAbs results in a 
complete disappearance o f the ELISA signal, dem onstrating  
the specificity o f the ELISA. The recovery of chemically 
cross-linked uPA:uPAR complexes added to  tu m o r extracts  
varies between 80% and 105%. The in tra- and inter-assay 
variation coefficients are 5.3% and 9.8%, respectively. Further­
more, a peptide antagonist fo r uPAR was employed to  
evaluate de novo uPA:uPAR complex form ation during tu m o r  
tissue extraction and the immunoassay procedure. O ur re­
sults strongly indicate th a t de novo complex form ation is a 
m ajor factor to  consider and tha t complexes analyzed in the  
presence o f this antagonist represent original uPA:uPAR  
complexes present p rio r to  tu m o r tissue processing. The 
present ELISA appears suitable fo r studying the potential 
prognostic impact o f uPAiuPAR complexes in lung tu m o r  
tissue as well as other types of cancer, /nt. J. Cancer 72:416- 
423, 1997.
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The plasminogen activation system represents a complex cas­
cade of proteolytic enzymes which, in concert with other enzyme 
systems, is involved in the degradation of extracellular matrix 
proteins during tissue remodeling processes under normal and 
pathological conditions, including cancer invasion (Dan0 et a l , 
1985; Blasi eta i, 1987; Mignatti and Rifkin, 1993). The urokinase- 
type plasminogen activator (uPA) plays a key role in this system in 
that it activates the zymogen plasminogen into plasmin, which has 
a broad trypsin-like substrate specificity and the ability to degrade 
several components of the extracellular matrix (Dan0 et aL, 1985; 
Mignatti and Rifkin, 1993; Duffy, 1992). uPA itself is synthesized 
and secreted as an inactive single polypeptide chain pro-enzyme, 
pro-uPA, which is converted by plasmin and certain other proteases 
into its active 2-chain counterpart (Petersen et al., 1988; Pollanen et 
al., 1991). The overall activity of the plasminogen-activation 
system is potentiated by the binding of pro-uPA to a specific 
cellular receptor, uPAR, which localizes proteolysis to the cell 
surface and strongly enhances activation of surface-bound plasmino­
gen (Dan0 et al., 1994).
lmmunohistochemistry and in situ hybridization studies have 
demonstrated that both uPA and uPAR in adenocarcinoma of colon 
(Gr0ndahl-Hansen et al, 1991; Pyke et al, 1991) and breast (Pyke 
et al, 1993) and in squamous cell carcinoma of the skin (Sappino et 
al, 1991) are consistently expressed at invasive loci, either by the 
same cells or by closely located cells, Other investigations have 
shown that in carcinomas of breast (Gr0ndahl-Hansen e ta l,  1993), 
colon (Verspaget et al, 1995) and bladder (Hasui et al, 1996) uPA 
can be considered as an independent and significant prognostic 
marker, high uPA levels being associated with poor prognosis. In 
addition, elevated levels of uPAR were found to be of prognostic
value in patients with squamous cell lung carcinoma and breast 
cancer (Pedersen et al., 1994; Gr0ndahl-Hansen et al, 1995). 
Furthermore, the interplay between uPA and uPAR is an important 
factor in the invasiveness of malignant cells and suggests that only 
receptor-bound uPA is active during invasion (Quax et al, 1991; 
Ossowski, 1988; Ossowski et al.t 1991; Ellis et a l, 1992), 
Therefore, it is assumed that the number of complexes between 
uPA and uPAR may better reflect the activity of the plasminogen- 
activation system and might represent an even stronger prognostic 
parameter.
In the present study, we describe the development of an ELISA 
for the specific detection and quantification of uPA:uPAR com­
plexes in extracts of squamous cell lung carcinoma tissue, using a 
combination of polyclonal antibodies and monoclonal antibodies 
(MAbs) previously employed in the ELISA for the separate 
components (Rosenquist et a l , 1993; R0nne et al, 1995). Different 
buffers were tested for optimal extraction of complexes out of the 
tumor tissue, The usefulness of a peptide antagonist for uPAR was 
investigated in order to analyze original uPAiuPAR complexes in 
tumor tissue extracts.
MATERIAL AND METHODS
Reagents
The following reagents were from the sources indicated: recom­
binant pro-uPA (Griinenthal, Aachen, Germany), active human uPA 
(Serono, Aubonne, Switzerland), tissue-type plasminogen activator 
(tPA) purified from culture fluid of Bowes melanoma cells (Nielsen 
et al, 1988), soluble variant of uPAR (s-uPAR) purified from 
Chinese hamster ovary (CHO) cells (R0nne et al, 1995), purified 
35S-labeled s-uPAR obtained after in vivo labeling of CHO cells 
(Ploug et al, 1993), protein A Sepharose and CNBr-activated 
Sepharose (Pharmacia, Uppsala, Sweden), horseradish peroxidase- 
conjugated streptavidin (Zymed, South San Francisco, CA), o- 
phenylenediamine (Dako, Glostrup, Denmark), BSA fraction V 
(Boehringer Mannheim, Germany), 1 -ethyl-3-(3-dimethylaminopro- 
pyl)carbodiimide (EDC) and sulfo-N-hydroxysulfosuccinimide 
(NHS) (Pierce, Rockford, IL). Peptide antagonist (clone 20) for 
human uPAR and a randomized control peptide (Goodsoti et a l } 
1994) were synthesized by Dr. J. Keyte (Department of Biochemis­
try, University of Nottingham, Nottingham, UK).
Tumor tissue and extraction
Non-small cell lung cancer (NSCLC) tissue was obtained from 
patients after surgical resection for a primary lung tumor at the 
Department of Thoracic Surgery, Rigshospitalet, Copenhagen, 
Denmark and immediately stored at — 80°C. Tumor tissue from 6
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randomly selected patients was mechanically pulverized in the 
frozen state with a pre-cooled powder pistol and then mixed. Next, 
the pooled material was divided into equal portions and homog­
enized in each of 3 different ice-cold buffers (buffers A, B and C, 
see below), using a tumor.buffer ratio (w/v) of 1:3. After centrifuga­
tion at 105,000 g for 1 hr at 4°C, supematants were aliquoted and 
stored at — 80°C until further analysis. In the same way, NSCLC 
tissue samples of 20 other randomly selected patients were each 
subjected to extraction with buffers A, B and C. To study de novo 
complex formation between uPA and uPAR, additional NSCLC 
biopsies of 13 patients were obtained from the Department of 
Pathology, University Hospital Nijmegen, The Netherlands, and 
frozen in liquid nitrogen immediately after surgery. Each tumor 
biopsy was pulverized in the frozen state by means of a microdis- 
membrator (B. Braun Biotech, Melsungen, Germany) in the 
presence of buffer C supplemented with 100 ¡nM of peptide 
antagonist or control peptide. For the processing of these tumors, a 
ratio (w/v) of 1:30 was used. After thawing on ice, homogenates 
were centrifuged at 105,000 g for 1 hr at4°C and the supematants 
stored at — 80°C until further analysis. Three different buffers, each 
of which had been used previously for optimal extraction of steroid 
hormone receptors (buffer A), uPA (buffer B) and uPAR (buffer C), 
respectively, were tested for their extraction efficiency of uPA: 
uPAR complexes. The composition of the 3 buffers was: (/) 10 mM 
K2HPO4/KH2PO4, 1.5 mM K2-EDTA, 10 mM monothioglycerol, 
10% (v/v) glycerol and 10 mM sodium molybdate, pH =  7.5 
(Thorpe, 1987); (ii) 75 mM potassium acetate, 0.3 M NaCl, 0.1 M 
L-arginine, 10 mM EDTAand 0.25% (w/v) Triton X-100, pH =  4.2 
(Camiolo et ai, 1982); (iii) 0.1 M Tris/HCI (pH -  8.1), 1% (w/v) 
Triton X-l 14, 10 mM EDTA and 10 pg/ml aprotinin (Behrendt et 
ai., 1990). Samples prepared with buffer C should include 0.25% 
3-[(3-cholamidopropyl)dimethyl-ammonio]-l-propanesulfonate 
(CHAPS) to avoid phase separation during subsequent steps caused 
by Triton X -114 at temperatures above 4°C.
Antibodies
Polyclonal rabbit antibodies raised against human uPA were used 
as catching antibodies in the ELISA (Rosenquist et al., 1993). 
Biotinylated anti-uPAR clone R2 was used as detecting antibody in 
the ELISA (R0nne et cd., 1991). Mouse MAbs against human uPA 
and human uPAR were used for im mu no-absorption of uPA and 
uPAR, respectively. Anti-uPA clone 1 and clone 2 specifically 
recognize epitopes in the A- and B-chains of uPA, respectively 
(Rosenquist et a i , 1993; Kaltoft et a/., 1982). Anti-uPA clone 14 
binds to the amino-terminal fragment (ATF) of uPA and is 
supposed to prevent complex formation with uPAR (data not 
shown). The mouse MAbs directed against human uPAR, clones 
R3 and R9, are directed against epitopes in domain 1 of uPAR; 
clone R3 does not recognize uPAR when in complex with uPA 
(R0nne et a l, 1991). Anti-uPAR clones R2 and R4 are directed 
against different epitopes in either domain 2 or domain 3 of uPAR 
(R0nne et ai., 1991). A MAb against 2,4,6-trinitrophenol (TNP) 
(Schulman et at., 1978) was used as a control.
Preparation o f uPA:uPAR complexes
iiPA:uPAR in vitro complex preparation. Complexes of pro-uPA 
with s-uPAR were prepared by mixing both components (100 
pmol/ml and 125 pmol/ml final concentrations, respectively) in
PBS (1.5 mM KH2P 0 4, 8.1 mM Na2H P04, 2.7 mM KC1, 0.14 M 
NaCl, pH =  7.4), containing 1% BSA and 0.1% (v/v) Tween-20, 
followed by incubation at room temperature for 1 hr. The mixture, 
referred to as in vitro complex preparation, was aliquoted and 
stored at — 80°C. Dilutions of this preparation, containing uPA: 
uPAR complexes as well as the free components, were used in all 
experiments for establishment of the ELISA.
uPA:uPAR complex standard. The uPA:uPAR complex standard 
was prepared by mixing pro-uPA with s-uPAR (1 pmol/ml and 12.5 
pmol/ml final concentrations, respectively) in buffer C. The 
mixture was incubated overnight at 4°C and aliquots were stored at 
—80°C. The excess of s-uPAR was demonstrated to completely 
saturate all pro-uPA. The standard curve was obtained by dilution
of the uPA:uPAR complex standard in the appropriate assay buffer, 
the working range corresponding to 0-40 fmol/ml.
uPAuiPAR cross-linked complexes. For preparation of cross- 
linked uPA:uPAR complexes, equal amounts of pro-uPA and 
s-uPAR (400 pmol/ml and 500 pmol/ml final concentrations, 
respectively) diluted in PBS containing 0.1% (v/v) Tween-80 were 
incubated for 30 min at 4°C, after which cross-linking was initiated 
by the addition of EDC and sulfo-NHS ester (10 mM, final 
concentration each). After 20 min incubation at room temperature, 
ammonium acetate was added to a final concentration of 10 mM, 
followed by another incubation for 10 min. The incubation mixture 
was analyzed on a 6-16% gradient SDS-PAGE gel under reducing 
conditions, showing approximately 25% of uPA and uPAR being 
cross-linked (results not shown). Cross-linked complexes were 
further purified by a 2-step immuno-adsorption, using polyclonal 
anti-uPA and polyclonal anti-uPAR antibodies covalently coupled 
to CNBr-activated Sepharose according to standard procedures 
(Behrendt et al., 1990). When dilutions of cross-linked complexes 
were analyzed in the complex ELISA, a linear dose-response was 
observed and supplementation of the preparation with increasing 
amounts of pro-uPA or s-uPAR (up to 400 fmol/ml and 500 fmol/ml 
final concentrations, respectively) did not evoke a signal increase, 
indicating the absence of free uPA and/or uPAR (results not 
shown). Analysis of the cross-linked preparation in the ELISA for 
uPAR (R0nne et al., 1995) using only biotinylated MAb R3 for 
detection, gave no signal above background level as compared to 
the signal evoked by purified s-uPAR alone (data not shown).
ELJSA fo  r u PA: uPAR comp I exes
The ELISA performed was essentially equal to the procedure 
described for the measurement of uPAR (R0nne et ai, 1995), 
Briefly, microtiter plates were coated overnight at 4°C with purified 
polyclonal anti-uPA IgG as catching antibody (1.0 ¡ug/ml; 100 
jul/well). After washing, subsequent blocking and rewashing the 
plates, the in vitro complex preparation, uPA:uPAR complex 
standard, cross-linked complexes or samples to be tested, diluted in 
PBS with 1% BSA and 0.1% (v/v) Tween-20 (100 jjl/well), were 
incubated in the plates for 60 min at 37°C, unless otherwise stated. 
After washing, plates were incubated for 60 min with biotinylated 
monoclonal anti-uPAR clone R2 as detection antibody (0.3 |ig/ml, 
100 pl/well), then washed again prior to incubation for 60 min with 
peroxidase-conjugated streptavidin diluted 4,000 times in PBS-BSA- 
Tween (100 jitl/well). Finally, plates were washed and the peroxi­
dase reaction initiated by the addition of substrate (0 .02% o- 
phenylenediamine, 0.01% H2O2, 100 pl/well). The reaction was 
stopped after 30 min incubation in darkness and the absorbance 
read at 492 nm (reference wavelength 620 nm) with an automated 
ELISA reader (AR 2001; Anthos, Salzburg, Austria). All determina­
tions were performed in duplicate.
Protein analysis
The Bradford (1976) method for protein analysis was employed 
using the Bio-Rad (Richmond, CA) reagent with BSA as a 
standard.
Statistics
Correlations between variables were evaluated with the Spear­
man rank order test using the Statistical Analysis System (SAS 
Institute, Cary, NC). Statistical values of p < 0.05 were considered 
significant.
RESULTS 
ELISA for uPA:uPAR complexes
In the complex ELISA there was a linear relationship between 
absorbance and uPA:uPAR complex standard up to at least 40 
fmol/ml (Fig. 1 a). Fixed dilutions of the in vitro complex prepara­
tion analyzed in this ELISA also showed a linear dose-response 
(Fig. 1 a). When the polyclonal anti-uPA catching antibody was 
substituted with IgG from a non-immunized rabbit, no signal above 
background level was observed with the uPA:uPAR in vitro
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F ig u r e  1 -  Dose-response curves in the complex ELISA. (a) Different concentrations of the uPA:uPAR complex standard (bottom x  axis) were 
assayed in the complex ELISA after overnight incubation at 4°C ( • - • ) .  Dilutions (1:1,250 to 1:40,000; top x  axis) of the uPA:uPAR in vitro 
complex preparation (0 -0 )  also were tested in the complex ELISA. As a control, uPA:uPAR in vitro complexes were tested when the rabbit 
polyclonal anti-uPA catching antibody was substituted with non-immune rabbit IgG (V-V) and when the biotinylated anti-uPAR antibody clone 
R2 was substituted with biotinylated anti-TNP MAbs (Y-Y). (/;) A fixed dilution (1:1,250) of the in vitro complex preparation was mixed 1:1 with 
the indicated (final) concentrations of pro-uPA ( • - • )  or s-uPAR ( 0 - 0 )  and analyzed in the complex ELISA.
complex preparation (Fig. I a). Similarly, when the biotinylated 
monoclonal anti-uPAR detection antibody (R2) was substituted 
with biotinylated anti-TNP, no signal was detected (Fig. I a). 
Addition of pro-uPA (0-1,000 fmol/ml) or s-uPAR (0-1,250 
fmol/ml) to the in vitro complex preparation led to an increased 
signal in the complex ELISA, most probably due to additional 
complex formation with the free components (Fig. 1 b). The 
declining signal obtained with the highest concentration of added 
pro-uPA indicates competition of uPA with uPA:uPAR complexes 
for binding to the catching antibodies. The response obtained when 
adding increasing amounts of s-uPAR indicates complex formation 
with uPA, leading to exhaustion of free uPA and/or saturation of the 
solid-phase binding sites (Fig. 1 b). Background levels were 
measured when both pro-uPA and active human uPA, s-uPAR or 
tPA were analyzed individually up to 1,000, 1,250 and 715 fmol/ml 
final concentrations, respectively (results not shown). When the in 
vitro uPA:uPAR complex preparation diluted in buffer C was 
absorbed with a mixture of either anti-uPA, clones 1 and 2, or 
anti-uPAR MAbs, clones R4 and R9, followed by precipitation 
with protein A Sepharose, a complete disappearance of the signal in 
the complex ELISA was observed as compared to the response 
obtained after addition of anti-TNP (Fig. 2a). A complete disappear­
ance in signal was also seen in the uPA ELISA after absorption with 
anti-uPA antibodies, while a partial decrease in signal was obtained 
after absorption with anti-uPAR IgG (Fig. 2a). Similarly, when 
analyzed in the uPAR ELISA, absorption of the in vitro complex 
preparation with anti-uPA and anti-uPAR resulted in a partial and a 
complete decrease in signal, respectively (Fig. 2a). Comparable 
results were obtained when the absorption experiment was per­
formed with the in vitro complex preparation diluted in buffer A or 
B (results not shown). Absorption of an extract of the pooled lung 
tumor tissue prepared with buffer C with anti-uPA IgG (clones 1 
and 2) or anti-uPAR IgG (clones R4 and R9) also resulted in an 
almost complete reduction of the signals (approximately 90% and 
75%, respectively) in the complex ELISA (Fig. 2b). Comparable 
results were obtained when the absorption experiment was per­
formed with the pooled lung-tumor sample extracted with buffer A 
or B (results not shown).
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F ig u r e  2 -  Absorption of the uPA:uPAR in vitro complex prepara­
tion and of a pooled lung tumor sample extracted with buffer C. (¿/) A 
100 times diluted aliquot of the in vitro complex preparation in buffer C 
was incubated for 2 hr at room temperature in the presence of anti-uPA, 
clones 1 and 2 (white bars); anti-uPAR, clones R4 and R9 (hatched 
bars); or anti-TNP (black bars). Antibodies were diluted in PBS-BSA- 
Tween and added in a 1,000-fold molar excess relative to the cxpected 
molar concentrations of uPA and uPAR. After incubation, antibody- 
ligand complexes were precipitated with 25% (v/v) protein A Sepha­
rose in PBS-BSA-Tween and the supematants analyzed in the complex 
ELISA, uPA ELISA and uPAR ELISA. Indicated are the mean 
absorbance values + S.D. of duplicate determinations. (b) Non-small 
cell lung carcinoma tissue of 6 patients was pulverized and the tumor 
powder pooled and mixed. An aliquot of the resulting sample was used 
for extraction with buffer C. Equal portions of the extract were then 
absorbed as described above for the in vitro complex preparation and 
analyzed in the complex ELISA. Indicated are the mean absorbance 
values + S.D. of duplicate determinations. '
Dilutions of extracts from a pool of lung-cancer tissue prepared 
with buffers A, B and C assayed in the complex ELISA showed a 
linear dose-response for all three types of extract, the highest 
signals obtained for extracts prepared in buffer C (Fig. 3). When 
fixed amounts of chemically cross-linked uPA:uPAR complexes 
were added to the different extracts, parallelism was found with the 
dilution curve of the cross-linked complexes (Fig. 4a, b), indicating
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that the assessment of the complexes is not affected by other 
components in the biological samples. Recovery of cross-linked 
complexes in the samples at each standard point varied between 
80-90% (extracts prepared with buffer A) and 80-105% (extracts 
prepared with buffers B and C).
The intra-assay variation of the complex ELISA was determined 
by duplicate analysis of 10 independent 1:5 dilutions of the pooled 
lung tumor extract prepared with buffer C in one and the same 
ELISA plate; the coefficient of variation in the calculated concentra­
tions was 5.3%. The inter-assay variation was determined by 
analyzing the same pooled extract in a 1:5 dilution on 10 separate 
days, resulting in a coefficient of variation of 9.6%.
The sensitivity of the complex ELISA was calculated to be 0.5 
fmol/ml (0.05 fmol/well), defined as the lowest antigen concentra­
tion giving a signal higher than the background value plus 3 times 
the standard deviation of this latter value. Overall, the coefficient of 
variation of duplicate measurements was less than 5%.
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F igure 3 -  Analysis of different extracts of lung cancer tissue in the 
complex ELISA. Different dilutions of extracts of pooled lung cancer 
tissue (starting with 10% extract) prepared with buffer A (0 -0 ) ,  buffer 
B (V-V) and buffer C ( • - • ) .
Tumor tissue extraction with different buffers
Twenty individual NSCLC samples extracted with buffers A, B 
and C were analyzed in the complex ELISA, as well as in the 
ELIS As for uPA and uPAR (Table I). Extracts prepared with buffer 
B contained the highest concentrations of uPA, while extracts 
prepared with buffer C showed the highest concentrations of uPAR 
and uPA:uPAR complexes. When the uPA:uPAR complex levels 
were compared to one another, a highly significant correlation 
(Spearman correlation coefficient r = 0.78; p  = 0.0001) was found 
between extracts prepared with buffers A and C. The levels of 
uPA:uPAR complexes in extracts prepared with buffer B were 
shown not to be associated with the levels obtained for extracts in 
buffer A (r =  0.17; p ~  0.49) or C (r = 0.38; p — 0,10), respec­
tively. Additionally, highly significant correlations were found 
between the levels of uPA and uPA:uPAR complexes in both 
extracts prepared with buffers A (r = 0,91 ; p = 0.0001) and C 
(r = 0.94; p  — 0,0001). No correlation was found between the uPA 
and uPA:uPAR complex levels obtained in buffer B (r =  0.29; p -  
0,22). When comparing the uPAR and uPA:uPAR complex levels, 
weak but significant correlations were found for extracts prepared 
with buffers A (r = 0.79; p  =  0,0001), B (r =  0.66; p = 0.002) and 
C (0.70; p = 0,0007).
Complex formation between uPA and uPAR in vitro
To study the ability of uPA and uPAR to form complexes in 
buffers A, B and C, pro-uPA and radioactively labeled 35S-s-uPAR 
were mixed with each other in the respective buffers (Fig. 5). Stable 
uPA:uPAR complexes can be formed in both buffers A and C as 
shown by the presence of radiolabeled 15S-s-uPAR in the immuno- 
precipitate with anti-uPA antibodies (Fig, 5, panels I and III, lanes 1 
and 2), Complex formation seems to occur in buffer B in the 
absence of unlabeled s-uPAR (Fig. 5, panel II, lane 1), which most 
probably should be ascribed to de novo complex formation due to 
dilution of the sample when adding the respective antibodies and, 
consequently, elevation of the pH to more neutral values (pH =  6.0), 
allowing antibody-ligand interactions. This was verified by im- 
muno-precipitation in the presence of excess unlabeled s-uPAR, 
which completely out-competed radioactive s-uPAR in forming 
complexes with pro-uPA (Fig. 5, panel II, lane 2).
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F igure  4 -  Analysis of cross-linked uPA:uPAR complexes calibrated against the uPA:uPAR complex standard added to different extracts of a 
pooled lung carcinoma tissue sample, (a) Cross-linked complexes in assay dilution buffer (O-O) and in a 10-fold diluted extract of the lung tumor 
tissue prepared with buffer A ( • - • ) .  (b) Cross-linked complexes from a different preparation in assay dilution buffer (O-O) and in 10-fold 
dilutions of extracts prepared with buffer B (V-V) and buffer C ( • - • ) .
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TABLE I -  AN ALYSIS OF NSCLC SAMPLES FOR uPA, uPAR AND uPA:uPAR COMPLEXES EXTRACTED
WITH 3 DIFFERENT BUFFERS
Buffer
ii PA uPAR uPA:uPAR
fmol/ml fmol/mg fmol/ml fmol/mg fmol/inl fmol/mg
A 182.7 22.2 538.8 66.5 54.2 7.1
(25.0-554.7) (3.7-70.8) (152.6-1,401.3) (22.3-158.3) (0-627.9) (0-70.9)
B 1,688.0 270.5 437.2 81.2 57.9 9.5
(436.7—4,355.9) (70.0-720.4) (192.7-1,195.1) (31.0-197.7) (0-213.1) (0-41.3)
C 560.3 45.0 787.2 78.6 154.6 16.1
(155.1-1,950.8) (11.3-152.9) (308.3-1,540.0) (19.9-117.3) (19.1-1,296.5) (1.6-83.8)
Individual luug tumor tissue samples were each extracted with buffers A (n = 18 samples), B and C 
(n = 20 samples each) and subsequently analyzed for uPA, uPAR and uPA:uPAR complexes in the 
respective ELIS As. For analysis in the complex ELISA, extracts were diluted 1:10. Incubation of samples 
was performed for 1 hr at 37°C. Indicated are the median values and ranges (between parentheses) obtained 
by one single extraction. uPA, uPAR and uPA:uPAR complex levels (expressed in fmol/mg protein) in the 
different extracts were correlated to one another.
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F igure 5 -  Complex formation in 3 different buffers. Pro-uPA and 
35S-labeled s-uPAR, diluted separately in buffers A, B and C, were 
mixed (30 and 37.5 pmol/ml final concentrations, respectively) and 
incubated overnight at 4°C. Mixtures were divided into equal aliquots 
containing 750 fmol/ml of uPA and 937.5 fmol/ml of uPAR, to which 
either anti-uPA MAbs, clones 1 and 2, clone 14 or irrelevant IgG 
(anti-TNP) were added in the presence or absence of unlabeled s-uPAR; 
the antibodies and s-uPAR were diluted in PBS and added in 50- and 
100-fold molar excesses, respectively After overnight incubation at 
4°C, immune complexes were incubated for 1 hr at room temperature 
with 25% (v/v) protein A Sepharose in binding buffer (0.1 M Tris/HCl 
[pH = 8.1], 300 mM NaCl, 0.1% BSA, 0.1% CHAPS). Pellets 
obtained after centrifugation, 25 sec at 5,000 g and 4°C, were washed 
twice with binding buffer and twice with binding buffer without BSA. 
After the last washing step, protein was eluted from the Sepharose 
pellets by boiling in SDS sample buffer and analyzed by SDS-PAGE on 
a 6-16%  polyacrylamide gel. The presence of a radioactive band 
(35S-s~uPAR) in the autoradiogram demonstrates the ability of uPA and 
uPAR to form stable complexes in the respective buffers. Panels I, II 
and III correspond to complex formation in buffers A, B and C, re­
spectively. Panel IV corresponds to a control incubation of 35S-s-uPAR 
without pro-uPA added in buffer C; panel V corresponds to a control 
incubation of uPA and 35S-s-uPAR in buffer C, but binding buffer was 
added instead of protein A Sepharose. In each panel, lanes 1 and 2 
correspond to incubation with anti-uPA, clones 1 and 2, in the absence 
or presence of unlabeled s-uPAR, respectively; lanes 3 and 4 corre­
spond to incubation with anti-TNP in the presence of unlabeled s-uPAR 
and incubation with anti-uPA, clone 14, in the absence of unlabeled 
s-uPAR, respectively. As a reference, 35S-labeled s-uPAR is shown in 
lane VI. Arrow denotes electrophoretic mobility of standard protein 
(glutamate dehydrogenase, bovine liver) with an m.w. of approx. 50 kDa.
Inhibition o f  de novo uPAntPAR complex formation
To study the potential formation of uPA:uPAR complexes during 
tumor tissue extraction and during the sample incubation step in the 
ELISA, increasing concentrations of the peptide antagonist (Good- 
son etaL, 1994) were tested for inhibitory activity when combining 
different concentrations of pro-uPA and s-uPAR diluted in buffer C. 
The selected concentrations of pro-uPA and s-uPAR were compa­
rable to those measured in the 20 lung tumor extracts (Table I). The 
results shown in Figure 6a indicate that when the (final) concentra­
tions of uPA and uPAR are not higher than approximately 200 
fmol/ml and 250 fmol/ml, respectively, a concentration of at least 
50 |uM of peptide antagonist is capable of inhibiting complex 
formation between uPA and uPAR for more than 80%. Efficient
inhibition of complex formation is assured only when the tempera­
ture is kept at 4°C. At higher temperatures (e.g., 37°C), blocking of 
complex formation between uPA and uPAR in vitro is far from 
complete (data not shown), The control peptide did not have any 
inhibiting effect on de novo complex formation (Fig. 6/;). A 
concentration of 100 ¡jM of peptide antagonist and control pep­
tide was chosen for further analyses. When different dilutions of the 
cross-linked uPA:uPAR complexes were analyzed in the presence 
of 100 |uM of peptide antagonist and control peptide, identical 
signals were obtained in the complex ELISA, indicating no interfer­
ing effect of the peptide antagonist with the ELISA reagents (results 
not shown). When different dilutions of pre-formed in vitro com­
plexes in buffer C were tested in the presence of 100 \iM of peptide 
antagonist at 4DC, the peptide antagonist did not show any effect on 
the signal in the complex ELISA (Fig. 6c)- These data indicate that, 
at least in vitro, already existing uPA:uPAR complexes do not dis­
sociate in the presence of high concentrations of peptide antagonist. 
Again, at high temperatures (37°C), the signals obtained are not 
stable, most likely because of displacement of uPA from the 
receptor by the peptide antagonist (results not shown). Thirteen 
NSCLC tissue biopsies were processed in the presence of peptide 
antagonist and randomized control peptide and subsequently 
analyzed in the complex ELISA. As shown in Table II, extracts 
prepared in the presence of peptide antagonist contained lower 
concentrations of uPA:uPAR complexes when compared to extracts 
prepared with control peptide. The differences are most probably 
the result of de novo formation of uPA:uPAR complexes in the 
absence of peptide antagonist, the amount of which appears to vary 
between 55% and 353% of the amount of complexes measured in 
the presence of peptide antagonist. The same 13 extracts also were 
analyzed in the ELIS As for uPA and uPAR, to investigate relations 
between the levels of uPA:uPAR complexes and the concentrations 
of the separate components (Table II). All extracts scored uPA and 
uPAR levels below 200-250 fmol/ml, except for extract 5 (318.1 
fmol/ml uPA) and extract 13 (336.1 fmol/ml uPAR). Finally, the 
concentrations of the different molecules as determined in the 13 
NSCLC tissue extracts were correlated to one another. The 
calculated Spearman correlation coefficients were successively 
0.59 (/; -  0.03) for uPA vf. uPAR, 0.75 (p  =  0.003) for uPA vs. 
uPAiuPAR complex (extraction with control peptide), 0.86 
(p =  0.0002) for uPA vs. uPA:uPAR complex (extraction with 
peptide antagonist), 0.70 (p = 0.007) for uPAR vs. uPA:uPAR 
complex (extraction with control peptide) and 0.67 (p = 0.01) for 
uPA vs. uPA:uPAR complex (extraction with peptide antagonist). 
Moreover, a highly significant correlation was found between 
uPA:uPAR complex levels measured in the extracts with peptide 
antagonist and control peptide (r -  0.86; p = 0.0001).
DISCUSSION
In the present work, we have demonstrated the establishment of 
a sensitive ELISA for the specific detection of complexes between 
uPA and uPAR with a combination of polyclonal anti-uPA catching
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F i g u r e  6  -  Effect of the peptide antagonist on de novo complex formation and on the 
stability of pre-formed uPA;uPAR complexes in vitro, (a) Pro-uPA (0, 20, 50, 100, 200, 
1,000 and 2,000 fmol/ml final concentrations, as indicated along the j  axis) diluted in 
ice-cold buffer C supplemented with increasing concentrations of peptide antagonist or 
control peptide (0-200 pM filial concentrations) and s-uPAR (0,25,62.5, 125,250, L *250 
and 2,500 fmol/ml final concentrations) diluted in ice-cold buffer C without any 
supplementations were mixed 1:1. After incubation for 1 hr at 4°C, mimicking the 
centrifugation step when preparing the tumor tissue extracts, the mixtures were diluted 
1:10 with PBS-BSA-Tween supplemented with peptide antagonist or control peptide 
(0-200 pM final concentrations) and analyzed in the complex ELISA (incubation 
overnight at 4°C). The percentage of inhibiting activity by the peptide antagonist was 
calculated on the basis of the absorbances and expressed relative to the O.D. signals 
obtained with control peptide. Peptide concentrations: 10 pM 25 j jM  0 - 0  50 pM 
▼-T, 100 pM V-V, 150 pM and 200 pM (b) Pro-uPA (200 fmol/ml final 
concentration) and s-uPAR (250 fmol/ml final concentration) were incubated with each 
other in the presence of increasing concentrations of peptide antagonist or control peptide 
(0-200 pM final concentrations) and assayed in the complex ELISA as described for («). 
The percentages of inhibiting activity by the peptide antagonist ( 0 - 0 )  as well as that by 
the control peptide ( • - • )  were calculated on the basis of the absorbances and expressed 
relative to the O.D. signals obtained without peptide antagonist or control peptide, re­
spectively. (c) Different dilutions (1:5,000 to 1:20,000) of the in vitro complex prepa­
ration in buffer C supplemented with 100 pM of peptide antagonist (black bars) or control 
peptide (white bars) were analyzed in the complex ELISA (incubation overnight at 4°C). 
Indicated are the mean absorbance values + S.D. of duplicate determinations.
antibodies and one anti-uPAR MAb for detection. Thus far, the 
ELISAs developed for measurement of the constituents of the 
plasminogen activation system, i.e., uPA and uPAR, detect both 
the free forms and the respective components in complex with one 
another, without having the ability to distinguish between them. 
Moreover, these ELISAs detect each of the various forms with 
different efficiencies. Therefore, the assay results obtained from 
these ELISAs at best represent the total amount of uPA or uPAR 
present. Our study shows the establishment of an ELISA for the 
specific detection and quantitation of uPA:uPAR complexes in 
tumor tissue extracts.
The specificity of the complex ELISA is demonstrated by the 
absorption experiment with the in vitro complex preparation as 
well as the tumor tissue extracts using anti-uPA and anti-uPAR 
MAbs different from those employed in the assay. After incubation 
with both types of antibody, no responses in the complex ELISA 
were observed. Furthermore, pro-uPA, active uPA, uPAR, as well as 
tPA do not cause any signal in the complex ELISA. The specificity 
of the ELISA also is expressed by the absence of a response to the 
in vitro complex preparation when the polyclonal anti-uPA catch­
ing antibody or the biotinylated anti-uPAR detecting MAb was 
substituted with polyclonal non-immune IgG or biotinylated irrel­
evant MAb of the same sub class, respectively. The complex 
ELISA would not detect complexes of uPA with isolated domain 1 
of uPAR because the detection antibody (R2) was directed against 
domains 2 and 3 of the receptor. When uPAR is cleaved by uPA or
plasmin, as shown not only in vitro but also in vivo (H0yer-Hansen 
et al,  1992; Solberg et al., 1994), uPA in complex with the ligand- 
binding domain may be released. However, the apparent ligand-bind­
ing affinity of the isolated domain 1 is more than 1,500-fold lower 
compared to intact uPAR; therefore, complexes between uPA and 
domain 1 of uPAR are supposed to be very unstable, making it un­
likely for these complexes to be present in vivo (Ploug et al,  1994).
Of the 3 different buffers studied, buffer C is clearly the most 
efficient for extraction of uPA;uPAR complexes from lung tumor 
tissue. This is demonstrated by the high signals obtained in the 
complex ELISA when assaying the pooled lung tissue sample as 
well as the 20 individual lung tumor extracts prepared in buffer C. 
These results are in agreement with the concept that detergent- 
containing buffers are effective for extraction of uPAR and, thus, 
uPA:uPAR complexes out of membranes (Nielsen et al, 1988; 
Behrendt et al., 1990). As found previously and in the present 
study, extraction with buffer B yields the largest amounts of uPA 
(Rosenquist et al., 1993), while buffer C is most efficient for uPAR 
extraction (R0nne et al., 1995). The high concentrations of uPA and 
uPAR in extracts prepared with buffer B are not attended by high 
concentrations of uPA:uPAR complexes, which is consistent with 
the low pH (4.2) of this buffer, causing dissociation of the 
complexes. Indeed, low pH buffers have been used to release 
endogenous (pro-) uPA bound to uPAR in order to purify the 
receptor from cells (Behrendt et a l , 1993a). The instability of 
uPAiuPAR complexes at low pH is also clear from the analysis of
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TABLE II -  ANALYSIS OF 13 DIFFERENT NSCLC SAMPLES FOR itPA, uPAR AND
uPA:uPAR
Sample u PA ifmol/mg)
uPAR
(fmnl/miz)
uPA:uPAR
r/cContr.
(|'nu>l/mii)
AnLig.
(fmol/mg)
1 1 3 1 .9 1 9 7 .9 5 0 .6 2 3 .2 118
2 3 0 .8 3 0 .5 8 .5 2 .6 2 2 9
3 3 2 .2 3 8 .9 15 .7 3 .5 3 4 2
4 4 7 .9 1 5 2 .3 3 2 .2 7 .7 3 2 0
5 1 8 8 .4 1 1 6 .2 2 6 .6 11.0 141
6 4 5 .0 7 5 .8 14 .0 3 .4 3 1 6
7 1 2 7 .3 7 3 .1 3 3 .6 16 .6 103
8 13 7 .5 1 4 9 .2 5 5 .7 3 5 .8 5 5
9 67.1 11 6 .4 29 .1 10.7 171
10 110.8 8 4 .3 2 7 .6 11.9 133
11 9 0 .0 80 .1 2 2 .2 7 .9 18 2
12 3 5 .8 5 3 .0 9 .4 2.1 3 5 3
13 75 .1 1 9 1 .8 2 5 .8 12.1 113
Thirteen different King tumor tissue samples were each extracted 
with buffer C supplemented with peptide antagonist (Antag.) or control 
peptide (Contr.) and analyzed in the complex ELISA, as well as in the 
ELISAs for uPA and uPAR. Indicated values are means obtained by one 
separate extraction and assay of one (uPA and uPAR, 1:15) or 2 
(uPA:liPAR complexes, 1:2 and 1:5) independent dilutions. Extracts 
prepared in the presence of peptide antagonist and control peptide 
contained comparable concentrations of uPA and uPAR. To assure full 
antagonistic activity of the peptide, final concentrations of uPA and 
uPAR in tumor-tissue extracts were kept below 200-250 fmol/ml, 
because of which the tumonbuffer ratio (w/v) was changed to 1:30 as 
stated in “Material and Methods” , Incubation was performed over­
night at 4°C. uPA, uPAR and uPA:uPAR complex levels (expressed in 
fmol/mg protein) in the different extracts were correlated to one 
another; % indicates the degree of de novo complex formation, 
calculated as the relative difference between uPA:uPAR complex levels 
in extracts with peptide antagonist (equated to 0% de novo complex 
formation) and control peptide.
complex formation in buffer B in vitro using pro-uPA and 
radioactively labeled s-uPAR (Fig. 5). As a consequence, the 
signals obtained in the complex ELISA when assaying lung tumor 
tissue extracts prepared with buffer B are most probably the result 
of de novo complex formation during the sample incubation step 
after dilution with a neutral pH buffer in the ELISA. Formation of 
secondary complexes between uPA and uPAR from different parts 
of the tumor specimen during tumor tissue processing certainly 
also could contribute to additional complexes which were not 
present at the beginning of the extraction procedure. In view of 
these findings, the response of the clinical samples in the complex 
ELISA may be considered as a measure of the complex-forming 
potential in the samples but not directly equated to the amount of 
complexes present in the tissue specimen at the moment of 
extraction (see further below).
To study de novo complex formation between uPA and uPAR 
during preparation of the tumor tissue extracts and/or the sample 
incubation step in the ELISA, we employed a 17-mer peptide 
which has been shown to act as a potent antagonist for uPAR 
(Goodson et ai, 1994). This peptide was capable of inhibiting 
formation of complexes between pro-uPA and s-uPAR (in final 
concentrations of up to 200 and 250 fmol/ml, respectively) in vitro, 
though very high concentrations of peptide antagonist (100 jjM) 
were necessary. Under these conditions, half-maximal inhibition of 
complex formation was obtained with a peptide concentration just 
below 10 jjM. This value is in apparent contrast to the stated 
inhibition constant of the synthetic peptide for the uPA:uPAR 
interaction (IC50 approx. 10 nM) (Goodson et a i , 1994), which is 
most probably a reflection of the different assay conditions and the 
high levels of uPA and uPAR tested in a non-solid phase-dependent 
system. The peptide antagonist (100 ¡lxM) did not have any effect on 
existing uPA:uPAR complexes in vitro when the temperature was 
kept below 4°C instead of at 37°C, thus opening the possibility of 
distinguishing between original and de novo formed complexes. 
The instability of the complexes at higher temperatures most likely 
can be attributed to kinetics-related phenomena.
Assuming an analogous effect of the peptide antagonist in vivo, 
the complexes measured in the 13 NSCLC extracts in the presence 
of this peptide most likely represent original uPA:uPAR complexes 
which were present at the beginning of the tumor tissue processing. 
The way in which the tumor biopsies were processed, which comprises 
the recommended procedure— i.e., dismembration of the tumor 
tissue in the presence of extraction buffer C (tumonbuffer ratio 
[w/v] 1:30) supplemented with peptide antagonist (100 |liM ,  final 
concentration) at -196°C, thawing the tumor powder and buffer 
components on ice, centrifugation of the homogenates and analysis 
of the extracts in the ELISA overnight at 4°C— should ensure full 
antagonistic potential of the peptide and therefore almost complete 
blocking of de novo complex formation. Measurement of similar 
levels of uPA:uPAR complexes in 2 different dilutions (1:2 and 1:5) 
of the tumor extracts prepared with peptide antagonist suggests that 
the complexes do not dissociate upon dilution to this extent. The 
large difference between the complex levels detected in-the pres­
ence of peptide antagonist and control peptide is indicative of a 
large extent of de novo complex formation between uPA and uPAR. 
Moreover, the degree of de novo complex formation differed widely 
(55-353%) in the 13 individual samples. The actual complex levels 
were quite low compared to the levels of both uPA and uPAR, 
suggesting that the (total) levels of uPA and uPAR are determined 
mainly by the concentrations of the free components. However, the 
uPAiuPAR complex levels assayed in the presence of peptide antago­
nist do show a larger degree of variation (factor 17) compared to 
both the complex levels analyzed in the presence of control peptide 
and the levels of uPA and/or uPAR (factors 6 and 7). Interestingly, 
when the levels of uPA and uPAR were correlated to one another, a 
correlation coefficient of 0.59 (p  = 0.03) was found, whereas the 
partial correlation coefficient between the total levels corrected for 
the confounding complexes was calculated to be 0,14 (p — 0.67) 
(complexes with control peptide) and 0,05 (p = 0.88) (complexes 
with peptide antagonist). The absence of any correlation suggests 
that the uPA:uPAR complexes are indeed important contributors to 
the clinical significance of (total) levels of uPA and uPAR as 
measured in the corresponding ELISAs. Despite statistically signifi­
cant correlations between the level of either uPA or uPAR and the 
levels of uPA:uPAR complexes, only a clinical study will prove the 
surplus value of analysis of complexes over the (total) concentra­
tions of uPA and/or uPAR. The present assay may be considered 
suitable for studying the potential prognostic impact of uPA:uPAR 
complexes in lung tumor tissue extracts as well as other types of 
cancer. Especially for these kinds of studies, it is recommended that 
the peptide antagonist be employed for analysis of original uPA'.uPAR 
complexes instead of artificially formed de novo complexes.
Finally, several studies with invasion model systems, both in 
vitro (Quax et ai, 1991; Behrendt et ai, 1993b) and in vivo 
(Ossowski, 1988; Ossowski et cd., 1991; Ossowski and Reich, 
1983), indicate that blocking of the binding of uPA to uPAR results 
in the inhibition of invasion and/or metastasis, which represents a 
promising new approach for anti-invasive therapy. Previously, an 
ELISA was developed for studying ligand-binding interactions 
using an anti-uPAR MAb for catching and an anti-uPA MAb for 
detection (Behrendt et cd., 1993a). Furthermore, a microtiter 
plate-based chromogenic assay has been described to identify 
substances which interfere with uPA binding to the receptor 
(Reltenberger et ai, 1995). The present ELISA, being completely 
characterized and above all optimized for quantitative detection of 
complexes between uPA and uPAR, could be of additional use for 
screening compounds inhibiting uPA:uPAR interactions.
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